Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, randomized, phase II study of the combination of docetaxel (Taxotere) and concomitant radiotherapy with or without cisplatin in patients with locally advanced head and neck cancer.

Next Previous
X
Search
Trial Profile

A multicenter, randomized, phase II study of the combination of docetaxel (Taxotere) and concomitant radiotherapy with or without cisplatin in patients with locally advanced head and neck cancer.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2010

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Docetaxel (Primary) ; Cisplatin
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Sponsors Sanofi

    • Most Recent Events

    • 08 Oct 2008 Actual end date changed from Oct 2007 to May 2006 added as reported by ClinicalTrials.gov.
    • 05 Oct 2008 Actual number of patients (86) added as reported by CT.gov
    • 20 Jul 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top